Association of Private Health Insurances, Cologne, and Department of Psychiatry, University of Frankfurt, Germany.
Int J Psychiatry Clin Pract. 1998;2(4):265-73. doi: 10.3109/13651509809115372.
Sertindole is a limbic-selective antipsychotic agent with a strong affinity for D2, 5-HT2 and α1-adrenergic receptors. Prolongation of the QT interval and other adverse cardiac or cardiovascular reactions are known effects of most antipsychotic drugs. For this reason such effects have been extensively monitored during clinical trials of sertindole. A small proportion of sertindole-treated patients were found to exhibit an increase in QT interval. Detailed analysis revealed no increased risk with sertindole of lethal complications due to an increase in QT interval. Nevertheless, as with other antipsychotics, electrocardiogram (ECG) recordings should be made prior to starting and during treatment with sertindole.
赛乐特是一种具有强烈亲和力的选择性抗精神病药,对 D2、5-HT2 和α1-肾上腺素能受体。延长 QT 间期和其他不良心脏或心血管反应是大多数抗精神病药物的已知作用。由于这个原因,在赛乐特的临床试验中,这些作用得到了广泛的监测。发现一小部分赛乐特治疗的患者表现出 QT 间期延长。详细分析显示,赛乐特不会增加因 QT 间期延长而导致致命并发症的风险。然而,与其他抗精神病药物一样,在开始使用赛乐特和治疗期间应进行心电图(ECG)记录。